-- The D-Domain binder has a fast off-rate and contributes to anito-cel’s differentiated pharmacology profile in multiple myeloma -- -- A simulation model of CAR T use...
-- Anito-cel demonstrated 96% ORR and 74% CR/sCR at a median follow-up of 15.9 months; responses continue to deepen over time -- -- Overall MRD negativity was...
Saturday, December 6, 2025 at 8:00 p.m. ET
-- A more recent data cut will be shared during an oral presentation for the iMMagine-1 study -- -- To date, no delayed neurotoxicities, including no Parkinsonism, no...
Arcellx Inc received a Buy rating and a $129.00 price target from Stifel Nicolaus analyst Stephen Willey today. The company’s shares closed yesterday at $92.37.Elevate Your Investing Strategy: Take advantage...
Canaccord Genuity analyst John Newman maintained a Buy rating on Arcellx Inc today and set a price target of $121.00. The company’s shares closed yesterday at $87.33.Elevate Your Investing Strategy:...
In a report released today, Eric Schmidt FCA from Cantor Fitzgerald maintained a Hold rating on Arcellx Inc. The company’s shares closed yesterday at $88.29.Elevate Your Investing Strategy: Take advantage...
Bank of America Securities analyst Jason Gerberry maintained a Buy rating on Arcellx Inc today and set a price target of $112.00. The company’s shares closed yesterday at $82.24.Elevate Your Investing...
Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced...